Evidence map›Paper›PMID 41084575›Full record

ArticleIndian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025

Serum Erythropoietin Level in Polycythemia Vera: Is a New Cut-Off Possible?

Rafet Eren, Abdulkadir Karismaz, Ceyda Arslan, Esra Terzi Demirsoy, Aliihsan Gemici, Istemi Serin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rafet ErenDepartment of Hematology, Faculty of Medicine, Biruni University, Istanbul, Turkey.
Abdulkadir KarismazDepartment of Hematology, University of Health Sciences, Istanbul Training and Research Hospital, Istanbul, Turkey.
Ceyda ArslanDepartment of Hematology, Istinye University, Liv Hospital Bahcesehir, Istanbul, Turkey.
Esra Terzi DemirsoyDepartment of Hematology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey.
Aliihsan GemiciDepartment of Hematology, Izmir Democracy University, Buca Training and Research Hospital, Izmir, Turkey.
Istemi SerinDepartment of Hematology, University of Health Sciences, Istanbul Basaksehir Cam and Sakura City Hospital, Basaksehir, Istanbul, Turkey.ORCID https://orcid.org/0000-0003-1855-774X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycythemia vera (PV) is a myeloproliferative disease characterized by hemoglobin/hematocrit levels above 16.5 g/dL or 49% in men, and 16 g/dL or 48% in women and accompanied by Supplementary Information: The online version contains supplementary material available at 10.1007/s12288-025-01990-4.

Indexed as

Cut-offDiagnosisErythropoietinPolycythemia vera

Identifiers

PMID41084575
PMCPMC12515172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.